The translocator protein (18 kDa): central nervous system disease and drug design.
Scarf
Alana M
AM
Brain and Mind Research Institute, 100 Mallett Street, Camperdown, NSW 2050, Australia.
Ittner
Lars M
LM
Kassiou
Michael
M
D000081:Acetamides / Q000494:pharmacology; D017209:Apoptosis / Q000502:physiology; D002490:Central Nervous System / Q000502:physiology*; D002493:Central Nervous System Diseases / Q000188:drug therapy / Q000503:physiopathology; D015195:Drug Design; D006801:Humans; D007210:Indoleacetic Acids / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D051336:Mitochondrial Membranes / Q000502:physiology; D019636:Neurodegenerative Diseases / Q000188:drug therapy / Q000503:physiopathology; D010647:Phenyl Ethers / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D018079:Receptors, GABA / Q000737:chemistry / Q000187:drug effects / Q000502:physiology
D000081:Acetamides; D007210:Indoleacetic Acids; D007211:Indoles; D010647:Phenyl Ethers; D011720:Pyrazoles; D011743:Pyrimidines; D018079:Receptors, GABA; C499229:TSPO protein, human; C015950:indoleacetamide